Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesevatinib Long-Term Extension in ADPKD
NCT02616055Phase 2Terminated
- Sponsor
- Kadmon
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tesevatinib in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Kadmon. Started Dec 2015; status: terminated.
02
Drugs
tesevatinib
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT02616055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616055.